|

Combined therapy of anlotinib and aumolertinib Clinical Trials

1 actively recruiting trial

Top Sponsors

  • Kunming Medical University1

Indications

  • Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor1
  • Lung Cancer1
  • Cancer1

Other1 trial

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.